HUE029454T2 - Von willebrand faktor (VWF)-tartalmú készítmények, valamint ehhez kapcsolódó eljárások, készletek és alkalmazások - Google Patents
Von willebrand faktor (VWF)-tartalmú készítmények, valamint ehhez kapcsolódó eljárások, készletek és alkalmazások Download PDFInfo
- Publication number
- HUE029454T2 HUE029454T2 HUE10830777A HUE10830777A HUE029454T2 HU E029454 T2 HUE029454 T2 HU E029454T2 HU E10830777 A HUE10830777 A HU E10830777A HU E10830777 A HUE10830777 A HU E10830777A HU E029454 T2 HUE029454 T2 HU E029454T2
- Authority
- HU
- Hungary
- Prior art keywords
- leu
- val
- ser
- cys
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (7)
- VON WILLEBRAND FAKTOR (VWF)-TARTALMÚ KÉSZÍTMÉNYEK, VALAMINT EHHEZ KAPCSOLÓDÓ ELJÁRÁSOK, KÉSZLETEK ÉS ALKALMAZÁSOK Szabadalmi igénypontok1,. Poíípeptíd. amely tartalmaz egy első arninosav-szekvenaát amely eiofordut egy vWF^pölipepííciben, és egy, m elsővel heterolőg mámáik amínösav-szekvenciái, amely poilpepiid képes kötni FVIILat és dlrnereket, eligomereket és mulhmerekei képezni, azzal a .megkötéssel, hogy a polipeptkJbőt hiányzik legalább a 04.,; B1, Bf, 83, CI, C2: és OK vWF~dornén; és a második aminoaav-oxeioeeeia egy ImmungloPulimFo-oek felel meg, amely második amioosav-szekveneia Oderminus az első andnesay-'Szekvenqlabpz, és m első ammesav-szakvencia a SEQ ID NO: 11 (azaz 11-es azonosítás) számé szekvencia), SEQ ID NO: 13 vagy SEQ ID NO. 15 szerinti.
- 2, Äz 1 > igénypont szerinti pokpepfid, ahol: a ρ o i I pe pé d - sze k ve n ci a a SEQ ID N0.2Ô, SEQ ID Nö:21 vagy SEQ. ID NQ:22 szedeti, t, Az 1. igénypont szerinti poilpeptid:, ahol a második aminossvmzekvenoia rendelkezik a SEQ ID NO;IS szerinti szekvenciával. 4» Készítmény, amely tartalmazza az 1. igénypont szedeti pollpeptkJet S, Fehérjekomplex, amely tartalmazza az 1. igénypont szerinti polipeptidet és az F Villát:. C Készítmény, amely tartalmazza az 5, igénypont szerinti féhegekomplexei ?, Nükteötidszekvencía, amely kódolja az 1;. igénypont szerint) polipeptidet. S. A ?.. igénypont szerinti nukleiXidszekvencia. amely nukleottdsxekvenelH a SEQ ID 'M0:23, SEQ 10 NÖ‘24 vagy SEQ 10 N028 szerinti. S, Expresszsos vektor, amely tartalmazza a 7. igénypont szennh nukíeotidszekvenoá!. 18* Sejt, amely expresszálja az 1. igénypont szerinti poiipeptidet
- 11. Sejt, amely expresszálja az 5 Igénypont szerinti íehénekomplexet
- 12. Eljárás m .5. igénypont szerinti féhérjekompiex előállítására, amely eljárás során érintkeztetjük az 1 igénypont szerinti poiipeptidet az FVHEcak 13. Â 12. igénypont szerinti eljárás, amelynél az: éríntkeztetés során tekembinánsan expresezÉltaijuk a poiipeptidet egy: sejtben, amely expresszáija az FVIII-at.
- 14. Eljárás FVIII in vitro előállítására, amely eljárás során érintkezíetjük az. FVHl-at az 1. igénypont szerinti polipeptiddei, hogy egy. a poiipeptidet és az FVHl-at tartalmazó fehérjekomplex képződjön, II, A 14, igénypont szerinti eljárás, amelynek serin továbbá szelektíven hözzátapasztjuk a komplexet egy gyantához, amely tartalmaz olyan kótöpartnert, amely affinitással rendelkezik egy, a második aminosav-szekvencia által meghatározott dóméit iránt. 18. A 13. igénypont szerinti eljárás, amelynél a kotopartner egy A-protein vagy egy G-protem 1?, Az 5. igénypont szerinti fehérjekomplex gyógyászati alkalmazásra, amelynél fokozott az FVIII egy plazmabe!! fannakókinetskaituiajöonsága,
- 18.. Az 5 igénypont szerinti fehérjekomplex a 17 igénypont szerinti alkalmazásra, amelynél a tulajdonság nyújtott plazmádéi! féiéieiidd.
- 19. Készítmény, amely tartalmazza az 5. igénypont szerinti lehénekomplezet, valamint egy gyógyászaiüag elfogadható hordozót. Ä A 19. igénypont szerinti készítmény véráltapot kezelésiben való alkalmazásra, 21, A 19. igénypont szerinti készítmény a Ä. Igénypont szerinti alkalmazásra, amelynél az állapot hemoflila
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26114509P | 2009-11-13 | 2009-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE029454T2 true HUE029454T2 (hu) | 2017-03-28 |
Family
ID=43992414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10830777A HUE029454T2 (hu) | 2009-11-13 | 2010-11-12 | Von willebrand faktor (VWF)-tartalmú készítmények, valamint ehhez kapcsolódó eljárások, készletek és alkalmazások |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8759293B2 (hu) |
| EP (1) | EP2499165B1 (hu) |
| JP (1) | JP5876416B2 (hu) |
| KR (1) | KR101808751B1 (hu) |
| CN (1) | CN102648212B (hu) |
| AU (1) | AU2010319425B2 (hu) |
| BR (1) | BR112012011740A2 (hu) |
| CA (1) | CA2780542C (hu) |
| CL (1) | CL2012001258A1 (hu) |
| ES (1) | ES2600879T3 (hu) |
| HK (1) | HK1170244A1 (hu) |
| HU (1) | HUE029454T2 (hu) |
| IL (1) | IL219679A (hu) |
| MX (1) | MX2012005527A (hu) |
| NZ (1) | NZ600278A (hu) |
| PL (1) | PL2499165T3 (hu) |
| PT (1) | PT2499165T (hu) |
| RU (1) | RU2579977C2 (hu) |
| WO (1) | WO2011060242A2 (hu) |
| ZA (1) | ZA201203795B (hu) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6263355A (ja) * | 1985-09-13 | 1987-03-20 | Hitachi Ltd | バツテリバツクアツプｒａｍのチエツク方法 |
| HUE026953T2 (hu) | 2007-06-01 | 2016-08-29 | Univ Maryland | Immunglobulin konstans régió FC-receptort kötõ ágensek |
| CA2772051C (en) | 2009-08-24 | 2020-08-18 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
| HUE029454T2 (hu) | 2009-11-13 | 2017-03-28 | Grifols Therapeutics Inc | Von willebrand faktor (VWF)-tartalmú készítmények, valamint ehhez kapcsolódó eljárások, készletek és alkalmazások |
| CA2902942C (en) | 2010-07-28 | 2020-12-22 | David S. Block | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions |
| AU2012324020A1 (en) | 2011-12-30 | 2013-07-18 | Grifols, S.A. | Method for purifying Factor VIII |
| CN104254614A (zh) | 2012-01-12 | 2014-12-31 | 比奥根艾迪克Ma公司 | 降低经受因子viii疗法的个体中针对因子viii的免疫原性的方法 |
| SI2804623T1 (sl) * | 2012-01-12 | 2020-02-28 | Bioverativ Therapeutics Inc. | Himerni polipeptidi faktorja VIII in njihove uporabe |
| EA201491470A1 (ru) | 2012-02-15 | 2015-01-30 | Амуникс Оперэйтинг Инк. | Композиции фактора viii и способы получения и использования подобных |
| NZ628014A (en) | 2012-02-15 | 2016-09-30 | Biogen Ma Inc | Recombinant factor viii proteins |
| EP2841451A1 (en) * | 2012-04-24 | 2015-03-04 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| RS59876B1 (sr) * | 2012-07-11 | 2020-03-31 | Bioverativ Therapeutics Inc | Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena |
| AU2013305885B2 (en) | 2012-08-20 | 2017-12-21 | Gliknik Inc. | Molecules with antigen binding and polyvalent Fc gamma receptor binding activity |
| DK2912186T3 (da) | 2012-10-24 | 2021-02-22 | Platelet Targeted Therapeutics Llc | Behandling rettet mod blodplader |
| GB201304973D0 (en) * | 2013-03-19 | 2013-05-01 | Profactor Pharma Ltd | Recombinant protein |
| ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
| EP3008084A2 (en) * | 2013-06-12 | 2016-04-20 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| WO2014210547A1 (en) * | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker |
| KR20240023705A (ko) * | 2013-06-28 | 2024-02-22 | 바이오버라티브 테라퓨틱스 인크. | Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 |
| WO2015021423A2 (en) * | 2013-08-08 | 2015-02-12 | Biogen Idec Ma Inc. | Purification of chimeric fviii molecules |
| TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| HRP20240640T1 (hr) | 2014-01-10 | 2024-08-02 | Bioverativ Therapeutics Inc. | Kimerni proteini faktora viii i njihova upotreba |
| US10626164B2 (en) | 2014-07-25 | 2020-04-21 | Csl Limited | Purification of VWF |
| US9701933B2 (en) * | 2014-09-19 | 2017-07-11 | Sarfaraz K. Niazi | Harvesting and purification or perfusion yielder (HAPPY) device |
| DK3265483T3 (da) * | 2015-03-06 | 2020-03-02 | CSL Behring Lengnau AG | Modificeret von Willebrand-faktor med forbedret halveringstid |
| CA2986626A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
| MX2017014872A (es) | 2015-05-22 | 2018-07-06 | Csl Behring Recombinant Facility Ag | Metodos para preparar factor de von willebrand modificado. |
| AU2016301303B2 (en) | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
| MX2018008293A (es) * | 2016-01-07 | 2018-09-21 | CSL Behring Lengnau AG | Factor de von willebrand mutado. |
| SG11201805497QA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
| US11034775B2 (en) | 2016-06-07 | 2021-06-15 | Gliknik Inc. | Cysteine-optimized stradomers |
| KR102175878B1 (ko) | 2016-06-24 | 2020-11-06 | 재단법인 목암생명과학연구소 | Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도 |
| EP3538133B1 (en) | 2016-11-11 | 2021-02-17 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
| US11890327B2 (en) | 2016-11-11 | 2024-02-06 | CSL Behring Lengnau AG | Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| BR112019009484A2 (pt) | 2016-12-09 | 2019-07-30 | Gliknik Inc | otimização de fabricação de gl-2045, um stradomer multimerizador |
| CN111132693A (zh) | 2017-04-20 | 2020-05-08 | 芝加哥大学 | 用与免疫治疗抗体连接的ecm亲和肽治疗癌症的方法和组合物 |
| GB201707139D0 (en) | 2017-05-04 | 2017-06-21 | Imp Innovations Ltd | Polypeptides |
| CA3068098A1 (en) | 2017-06-22 | 2018-12-27 | CSL Behring Lengnau AG | Modulation of fviii immunogenicity by truncated vwf |
| RU2766118C2 (ru) * | 2017-07-07 | 2022-02-08 | Такеда Фармасьютикал Компани Лимитед | Лечение пациентов с тяжелой формой болезни фон виллебранда, подвергающихся плановому хирургическому вмешательству, путем введения рекомбинантного ффв |
| US20200347116A1 (en) * | 2017-11-01 | 2020-11-05 | Queen's University At Kingston | Von willebrand factor proteins for treating bleeding disorders |
| MA52630A (fr) | 2018-05-18 | 2021-05-26 | Bioverativ Therapeutics Inc | Procédés de traitement de l'hémophilie a |
| US10654911B1 (en) | 2019-04-02 | 2020-05-19 | Beijing Neoletix Biological Technology Co., Ltd. | Vector co-expressing truncated von Willebrand factor and factor VIII |
| KR20220029733A (ko) | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf) |
| JP2023500953A (ja) | 2019-11-11 | 2023-01-11 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド |
| WO2024106355A1 (ja) * | 2022-11-14 | 2024-05-23 | セルジェンテック株式会社 | 血液凝固第ｖｉｉｉ因子改変体を産生するエクスビボ遺伝子治療用細胞 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234991A (en) | 1975-07-29 | 1993-08-10 | Pasteur Merieux Serums And Vaccines | Porous mineral support coated with an aminated polysaccharide polymer |
| US4652639A (en) | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
| US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| US5149637A (en) | 1987-04-06 | 1992-09-22 | Scripps Clinic & Research Foundation | Recombinant Factor VIIIC fragments |
| US5043429B1 (en) | 1987-05-01 | 1997-10-14 | Scripps Research Inst | Protein fragments containing factor VIII binding domain of von willebrand factor |
| FR2616437B1 (fr) | 1987-06-11 | 1990-09-07 | Ibf | Polymeres composites, leur preparation et leur utilisation en chromatographie liquide |
| US5200510A (en) | 1987-06-16 | 1993-04-06 | Zymogenetics, Inc. | Method for purifying factor viii:c, von willebrand factor and complexes thereof |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5683912A (en) | 1994-07-21 | 1997-11-04 | The Salk Institute For Biological Studies | Cloning and expression of a novel acetylcholine-gated ion channel receptor subunit |
| FR2632309B1 (fr) | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| FR2657884B1 (fr) | 1990-02-05 | 1994-09-02 | Tm Innovation | Procede pour la preparation du facteur viii humain et d'analogues du facteur viii. |
| US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
| US5661008A (en) | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
| ATE283864T1 (de) * | 1991-06-20 | 2004-12-15 | Aventis Behring L L C | Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor |
| DE4204694C3 (de) * | 1992-02-01 | 1995-10-12 | Octapharma Ag | Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5268097A (en) | 1992-06-19 | 1993-12-07 | Sepracor Inc. | Passivated and stabilized porous mineral oxide supports and method for the preparation and use of same |
| JP3560609B2 (ja) | 1992-11-13 | 2004-09-02 | イミュネックス・コーポレーション | Ｅｌｋリガンドと呼ばれる新規なサイトカイン |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| US5849989A (en) | 1994-10-07 | 1998-12-15 | Ontogeny, Inc. | Insulin promoter factor, and uses related thereto |
| US5688912A (en) | 1995-09-22 | 1997-11-18 | Bayer Corporation | Peptide ligands which bind to von willebrand factor |
| WO1997027331A2 (en) | 1996-01-23 | 1997-07-31 | Rapigene, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
| US6312893B1 (en) | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
| US6613508B1 (en) | 1996-01-23 | 2003-09-02 | Qiagen Genomics, Inc. | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques |
| AT403765B (de) | 1996-04-12 | 1998-05-25 | Immuno Ag | Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex |
| US6074832A (en) | 1996-07-19 | 2000-06-13 | The Regents Of The University Of Michigan | DNA encoding canine von Willebrand factor and methods of use |
| AU3671197A (en) | 1996-07-19 | 1998-02-10 | Regents Of The University Of Michigan, The | Dna encoding canine von willebrand factor and methods of use |
| US6063593A (en) | 1996-11-12 | 2000-05-16 | University Of Southern California University Park Campus | TGFβ1 responsive bone marrow derived cells to express a recombinant protein |
| AU729164B2 (en) | 1996-11-27 | 2001-01-25 | Genentech Inc. | Affinity purification of polypeptide on protein a matrix |
| AT406867B (de) | 1997-02-27 | 2000-10-25 | Immuno Ag | Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex |
| AT406373B (de) | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| US6489290B2 (en) | 1997-03-27 | 2002-12-03 | Trustees Of Boston University | Antiplatelet agent |
| US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
| HUP0002518A3 (en) | 1997-07-22 | 2003-01-28 | Qiagen Genomics Inc | Computer method and system for correlating sequencing data by ms |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP1129186B2 (de) | 1998-11-10 | 2016-11-30 | Stichting Sanquin Bloedvoorziening | Ein faktor viii-polypeptid mit faktor viii:c-aktivität |
| US7144996B1 (en) | 1999-03-05 | 2006-12-05 | Genentech, Inc. | Nucleic acid encoding human suppressor of fused |
| US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
| US20050164386A1 (en) | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
| US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US20060099685A1 (en) | 1999-04-15 | 2006-05-11 | Yallop Christopher A | Recombinant expression of factor VIII in human cells |
| CA2921260A1 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| JP2004509609A (ja) | 2000-06-02 | 2004-04-02 | ブルー ヘロン バイオテクノロジー インコーポレイテッド | 合成二本鎖オリゴヌクレオチドの配列忠実度を改善するための方法 |
| US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| US20050153383A1 (en) | 2000-07-28 | 2005-07-14 | Montgomery Robert R. | Synthetic and recombinant substrates for the detecion of the von willebrand factor-cleaving protease |
| AUPR278301A0 (en) | 2001-01-31 | 2001-02-22 | Bionomics Limited | A novel gene |
| JP2003284570A (ja) * | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | フォンビルブラント因子（ｖＷＦ）切断酵素 |
| WO2003025146A2 (en) | 2001-09-18 | 2003-03-27 | Avigenics, Inc. | Production of a transgenic avian by cytoplasmic injection |
| US7439043B2 (en) | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
| AU2002364509A1 (en) | 2001-11-30 | 2003-06-17 | Emory University | Factor viii c2 domain variants |
| AU2002357249A1 (en) | 2001-12-13 | 2003-07-09 | Blue Heron Biotechnology, Inc. | Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins |
| AU2002364587A1 (en) | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| MXPA05000552A (es) | 2002-07-15 | 2005-04-28 | Immunex Corp | Metodos y medios para controlar la sialilacion de proteinas producidas por celulas de mamifero. |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| AU2004239244C1 (en) * | 2003-05-06 | 2015-04-23 | Bioverativ Therapeutics Inc. | Clotting factor-Fc chimeric proteins to treat hemophilia |
| JP2005073528A (ja) * | 2003-08-28 | 2005-03-24 | Genetics Inst Llc | 生物学的系における生物学的組織への血球の接着を阻害する方法、ならびにその方法に使用するための組成物 |
| JP2007531707A (ja) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ， インコーポレイテッド | ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変 |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| ES2593318T3 (es) | 2004-08-12 | 2016-12-07 | Lipoxen Technologies Limited | Derivados de ácido siálico |
| WO2006029258A2 (en) | 2004-09-07 | 2006-03-16 | Archemix Corp. | Aptamer medicinal chemistry |
| GB0423974D0 (en) * | 2004-10-28 | 2004-12-01 | Ares Trading Sa | Proteins |
| CA2591852A1 (en) | 2004-12-27 | 2006-07-06 | Baxter International Inc. | Polymer-von willebrand factor-conjugates |
| CA2593328C (en) | 2005-01-14 | 2018-02-06 | Ablynx N.V. | Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between von willebrand factor (vwf) and platelets |
| EP1739179A1 (en) | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
| US20080206246A1 (en) | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| US9012605B2 (en) * | 2006-01-23 | 2015-04-21 | Amgen Inc. | Crystalline polypeptides |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| WO2007146959A2 (en) | 2006-06-12 | 2007-12-21 | Receptor Biologix Inc. | Pan-cell surface receptor- specific therapeutics |
| US8637007B2 (en) | 2006-12-15 | 2014-01-28 | Baxter International Inc. | Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life |
| EP2097096B1 (en) | 2006-12-22 | 2017-05-31 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| KR101627157B1 (ko) | 2007-12-27 | 2016-06-03 | 박스알타 인코퍼레이티드 | 샘플 내의 재조합 단백질로부터 혈장-유래 단백질의 분별 방법 |
| SG10201608059VA (en) | 2007-12-28 | 2016-11-29 | Baxter Int | Recombinant vwf formulations |
| DK2865760T3 (en) * | 2008-06-24 | 2018-01-15 | Csl Behring Gmbh | Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life |
| RU2011110459A (ru) | 2008-08-21 | 2012-09-27 | Октафарма АГ (CH) | Рекомбинантно полученный человеческий фактор viii и ix |
| US20110086362A1 (en) | 2009-10-09 | 2011-04-14 | Massachusetts Institute Of Technology | High-Throughput Method for Quantifying Sialylation of Glycoproteins |
| HUE029454T2 (hu) | 2009-11-13 | 2017-03-28 | Grifols Therapeutics Inc | Von willebrand faktor (VWF)-tartalmú készítmények, valamint ehhez kapcsolódó eljárások, készletek és alkalmazások |
-
2010
- 2010-11-12 HU HUE10830777A patent/HUE029454T2/hu unknown
- 2010-11-12 WO PCT/US2010/056496 patent/WO2011060242A2/en active Application Filing
- 2010-11-12 BR BR112012011740A patent/BR112012011740A2/pt not_active Application Discontinuation
- 2010-11-12 CA CA2780542A patent/CA2780542C/en active Active
- 2010-11-12 US US13/509,309 patent/US8759293B2/en active Active
- 2010-11-12 RU RU2012122402/10A patent/RU2579977C2/ru not_active IP Right Cessation
- 2010-11-12 PT PT108307778T patent/PT2499165T/pt unknown
- 2010-11-12 JP JP2012539007A patent/JP5876416B2/ja active Active
- 2010-11-12 NZ NZ600278A patent/NZ600278A/en not_active IP Right Cessation
- 2010-11-12 EP EP10830777.8A patent/EP2499165B1/en active Active
- 2010-11-12 AU AU2010319425A patent/AU2010319425B2/en active Active
- 2010-11-12 KR KR1020127013906A patent/KR101808751B1/ko active IP Right Grant
- 2010-11-12 CN CN201080051549.3A patent/CN102648212B/zh active Active
- 2010-11-12 PL PL10830777T patent/PL2499165T3/pl unknown
- 2010-11-12 ES ES10830777.8T patent/ES2600879T3/es active Active
- 2010-11-12 MX MX2012005527A patent/MX2012005527A/es active IP Right Grant
-
2012
- 2012-05-09 IL IL219679A patent/IL219679A/en not_active IP Right Cessation
- 2012-05-14 CL CL2012001258A patent/CL2012001258A1/es unknown
- 2012-05-24 ZA ZA2012/03795A patent/ZA201203795B/en unknown
- 2012-10-29 HK HK12110787.2A patent/HK1170244A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011060242A2 (en) | 2011-05-19 |
| JP2013510581A (ja) | 2013-03-28 |
| IL219679A (en) | 2016-11-30 |
| KR101808751B1 (ko) | 2017-12-13 |
| AU2010319425B2 (en) | 2015-07-02 |
| CA2780542C (en) | 2020-03-24 |
| CN102648212A (zh) | 2012-08-22 |
| BR112012011740A2 (pt) | 2018-03-27 |
| US8759293B2 (en) | 2014-06-24 |
| EP2499165A4 (en) | 2013-09-11 |
| HK1170244A1 (zh) | 2013-02-22 |
| CN102648212B (zh) | 2014-12-03 |
| ZA201203795B (en) | 2014-10-29 |
| PT2499165T (pt) | 2016-10-28 |
| CL2012001258A1 (es) | 2012-09-14 |
| US20120289468A1 (en) | 2012-11-15 |
| AU2010319425A1 (en) | 2012-06-14 |
| MX2012005527A (es) | 2012-08-08 |
| CA2780542A1 (en) | 2011-05-19 |
| WO2011060242A3 (en) | 2011-10-13 |
| KR20120113214A (ko) | 2012-10-12 |
| JP5876416B2 (ja) | 2016-03-02 |
| PL2499165T3 (pl) | 2017-04-28 |
| RU2579977C2 (ru) | 2016-04-10 |
| EP2499165B1 (en) | 2016-09-14 |
| ES2600879T3 (es) | 2017-02-13 |
| EP2499165A2 (en) | 2012-09-19 |
| RU2012122402A (ru) | 2013-12-20 |
| NZ600278A (en) | 2014-04-30 |
| IL219679A0 (en) | 2012-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101808751B1 (ko) | 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도 | |
| CN114736305B (zh) | 因子viii嵌合蛋白及其用途 | |
| KR102392142B1 (ko) | 다량체 il-15 기반 분자 | |
| KR101682496B1 (ko) | 혈관형성 유도인자를 길항하는 융합단백질 및 그 용도 | |
| US20210355473A1 (en) | Chimeric clotting factors | |
| CN111886241A (zh) | 多聚体t细胞调节多肽及其使用方法 | |
| DK2361932T3 (en) | CHEMICAL IMMUNOGLOBULIN MONOMER DIMER HYBRIDS | |
| JP2023075185A (ja) | 治療用ヌクレアーゼ組成物および方法 | |
| KR102228921B1 (ko) | Pdgf 및 vegf 결합 부분을 포함하는 융합 단백질 및 이의 이용방법 | |
| CN108465106B (zh) | 降低经受因子viii疗法的个体中针对因子viii的免疫原性的方法 | |
| US20160229903A1 (en) | Thrombin cleavable linker | |
| CN111499760A (zh) | 嵌合因子viii多肽及其用途 | |
| KR20180020305A (ko) | Viii 인자 키메라 및 하이브리드 폴리펩타이드, 그리고 이들의 사용 방법 | |
| CN101679497A (zh) | 可溶性il-17ra/rc融合蛋白以及相关方法 | |
| CN109336980B (zh) | 一种靶向Muc1的嵌合抗原受体修饰T细胞及其用途 | |
| CN112512555A (zh) | 治疗血友病a的方法 | |
| CN101198621A (zh) | 分子及其嵌合分子 | |
| CN101160322A (zh) | 分子及其嵌合分子 | |
| KR20240026896A (ko) | 항염증성 siglec 단백질 및 이의 제조 및 사용 방법 | |
| KR101625112B1 (ko) | 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도 |